Dr. Giuroiu has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Reidy-Lagunes has disclosed that she is on the advisory board for Novartis AG, Pfizer Inc., and Ipsen. She also receives research support from Novartis AG.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
Strosberg JR, Cheema A, Weber J et al.. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011;29:3044–3049.
Yao JC, Hassan M, Phan A et al.. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–3072.
Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998;21:36–38.
Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711–719.
Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 2009;38:255–258.
Roland CL, Bian A, Mansour JC et al.. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595–600.
Vezzosi D, Bennet A, Rochaix P et al.. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757–767.
Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013;34:228–252.
Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol 2009;6:143–152.
Jensen RT, Cadiot G, Brandi ML et al.; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98–119.
Ruszniewski P, Rougier P, Roche A et al.. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71:2624–2630.
Eriksson B, Larsson EG, Skogseid BM et al.. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–2301.
Gupta S, Yao J, Ahrar K et al.. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson Experience. Cancer 2003;9:261–267.
Moertel C, Johnson C, McKusick M et al.. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302–309.
Kennedy AS, Dezarn WA, McNeillie P et al.. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31:271–279.
Rhee TK, Lewandowski RJ, Liu DM et al.. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029–1035.
King J, Quinn R, Glenn DM et al.. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113:921–929.
Cao CQ, Yan TD, Bester L et al.. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010;97:537–543.
Strosberg JR, Fine RL, Choi J et al.. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–275.
Moertel CG, Lefkopoulo M, Lipsitz S et al.. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–523.
Cheng P, Saltz L. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944–948.
von Wichert G, Haeussler U, Greten FR et al.. Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 2005;24:1284–1289.
Reidy-Lagunes DL, Vakiani E, Segal MF et al.. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 2012;118:4795–4800.
Chandarlapaty S, Sawai A, Scaltriti M et al.. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58–71.
Reidy-Lagunes D, Pietanza MC, Segal M et al.. A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs). Presented at the 6th Annual Meeting of the North American NeuroEndocrine Tumor Society (NANETS); October 4–5, 2013; Charleston, NC.
- Search Google Scholar
- Export Citation
. Reidy-Lagunes D Pietanza MC Segal M A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs). Presented at the 6th Annual Meeting of the North American NeuroEndocrine Tumor Society (NANETS); October 4–5, 2013; Charleston, NC.
Oberg K, Casanovas O, Castano JP et al.. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res 2013;19:2842–2849.
Raymond E, Dahan L, Raoul JL et al.. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [published correction appears in N Engl J Med 2011;364:1082]. N Engl J Med 2011;364:501–513.
Hobday TJ, Qin R,Reidy-Lagunes D et al.. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 2014, in press.
Walderr C, Pless M, Maecke HR et al.. The clinical value of [90Y-DOTA]-dPhe-Tyr-octreotide in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941–945.
Waldherr C, Pless M, Maecke H et al.. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610–616.
Kwekkeboom DJ, de Herder WW, Kam BL et al.. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–2130.
Kwekkeboom DJ, Teunissen JJ, Bakker WH et al.. Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
Cassier PA, Walter T, Eymard B et al.. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. Cancer 2009;115:3392–3399.